CHA sent a comment letter to the FDA on draft guidance that recommends how and when manufacturers provide additional information in drug shortage notifications to the agency. Our letter urges the FDA to address the specific challenges facing the pediatric drug supply chain through transparency requirements, developing proactive shortage mitigation plans, and ensuring an accounting of pediatric drugs on the FDA drug shortages list.
CHA Submits Comments on FDA Drug Shortage Guidance
Children’s Hospital Association sends a comment letter to the FDA on draft drug shortage guidance to highlight the need for an efficient pediatric supply chain.
Related Content
CHA Applauds Actions Taken to Increase Access to Sickle Cell Disease Therapies
CHA Commends Bipartisan Congenital Heart Futures Reauthorization Act
Children's Hospital Association's 2024 End of Year Letter to Congress
CHA Applauds Actions Taken to Increase Access to Sickle Cell Disease Therapies
The Centers for Medicare and Medicaid Services (CMS) and the gene therapy manufacturers announce new agreement.
Dec. 05, 2024
CHA Commends Bipartisan Congenital Heart Futures Reauthorization Act
The act reauthorizes federal data collection, research, and awareness efforts on the diagnosis and treatment of congenital heart defects.
Dec. 04, 2024
Children's Hospital Association's 2024 End of Year Letter to Congress
The letter highlights CHA's end of year priorities and asks Congress to take action to sustain children’s hospitals’ ability to provide care to our nation’s children.
Nov. 20, 2024
